OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Paul Newhouse

2 Projects | 1 Researchers | $1,810,973 Invested

2016

Vanderbilt University

Paul Newhouse, MD

Phase 1 First-in-Human Multiple Ascending Dose Study of the Putative Cognitive Enhancer and M1 Positive Allosteric Modulator VU0467319

  • Funding Amount: $1,271,174
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2016

Vanderbilt University

Paul Newhouse, MD

Long-Term Nicotine Treatment of Mild Cognitive Impairment (MCI)

  • Funding Amount: $539,799
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed